CBD Earned FDA Approval for Two Severe Childhood Epilepsy Syndromes | Research

The takeaway

After decades of anecdotal evidence, high-quality randomized controlled trials led to FDA approval of purified CBD extract (Epidiolex) for Dravet and Lennox-Gastaut syndromes.

Parents of children with epilepsy, neurologists, medical cannabis policy makers.

50 million people worldwide have epilepsy; about one-third are drug-resistant and could benefit from new treatments like CBD.

What the researchers found

Early anecdotal evidence for cannabis as an anticonvulsant was recently replaced by high-quality data from randomized controlled studies. This led to FDA approval of purified CBD for two highly refractory pediatric epilepsy syndromes. About one-third of epilepsy patients are drug-resistant, defined as failure despite adequate trials of at least two appropriate medications.

Why it matters

The FDA approval of CBD for epilepsy represents a landmark moment - the first cannabis-derived prescription drug approved in the United States. It validates decades of patient advocacy and demonstrates that rigorous clinical trials can be conducted with cannabis compounds.

The numbers in context

Approximately 50 million people worldwide have epilepsy. About one-third (roughly 17 million) are drug-resistant. FDA approved purified CBD for Dravet and Lennox-Gastaut syndromes.

How the study worked

Review of evidence from early anecdotal reports through modern randomized controlled trials supporting CBD as an anticonvulsant.

What this study cannot tell us

Short review focused on the approval pathway. Does not deeply analyze trial data or long-term outcomes. Approval was limited to two specific syndromes.

How to read the evidence

Strong - based on randomized controlled trials that led to FDA approval.

When this study was published

Published in 2018, the year Epidiolex received FDA approval.

The bigger picture

The path from anecdotal cannabis-for-seizures evidence to FDA approval of a purified CBD product could serve as a model for how other cannabis-based medicines might gain regulatory acceptance through rigorous clinical trials.

Questions still open

Will CBD prove effective for other epilepsy types beyond Dravet and Lennox-Gastaut? Is purified CBD as effective as whole-plant extracts? What are the long-term effects of CBD use in children?

Common questions

Is CBD approved for epilepsy?

Yes. Purified CBD (Epidiolex) received FDA approval in 2018 for Dravet syndrome and Lennox-Gastaut syndrome, two severe forms of childhood epilepsy. This was the first cannabis-derived prescription drug approved in the US.

How many people with epilepsy don't respond to regular medications?

About one-third of epilepsy patients - roughly 17 million people worldwide - are drug-resistant, meaning seizures continue despite trying at least two appropriate medications.

Read the original research

Cannabidiol for Epilepsy: New Hope on the Horizon?

Clinical therapeutics, 40(9), 1438-1441

View on PubMed ↗Publisher’s paper ↗

Citation

Sanmartin, Paul E; Detyniecki, Kamil. (2018). Cannabidiol for Epilepsy: New Hope on the Horizon?. Clinical therapeutics, 40(9), 1438-1441. https://doi.org/10.1016/j.clinthera.2018.07.020